[PDF][PDF] Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
V Strand, D van der Heijde, Y Tanaka… - Clin Exp …, 2020 - clinexprheumatol.org
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) …
(RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) …
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
R Fleischmann, J Kremer, Y Tanaka… - International Journal …, 2016 - Wiley Online Library
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).
Here, the safety and efficacy data from five Phase 2 studies of tofacitinib in patients with RA …
Here, the safety and efficacy data from five Phase 2 studies of tofacitinib in patients with RA …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …
[HTML][HTML] Effect of discontinuation or initiation of methotrexate or glucocorticoids on tofacitinib efficacy in patients with rheumatoid arthritis: a post hoc analysis
R Fleischmann, J Wollenhaupt, S Cohen… - Rheumatology and …, 2018 - Springer
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). We evaluated the effect of concomitant methotrexate (MTX) or glucocorticoid …
arthritis (RA). We evaluated the effect of concomitant methotrexate (MTX) or glucocorticoid …
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
RM Fleischmann, TWJ Huizinga, AF Kavanaugh… - RMD open, 2016 - rmdopen.bmj.com
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage …
arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage …
[PDF][PDF] Tofacitinib in combination with conventional disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient‐reported outcomes from …
V Strand, JM Kremer, D Gruben… - Arthritis care & …, 2017 - Wiley Online Library
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with …
(RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with …
[HTML][HTML] Tofacitinib 5 mg twice daily in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs: a comprehensive review …
P Bird, W Bensen, B El-Zorkany, J Kaine… - JCR: Journal of …, 2019 - journals.lww.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). We performed a comprehensive review of phase 3 studies of tofacitinib 5 mg …
arthritis (RA). We performed a comprehensive review of phase 3 studies of tofacitinib 5 mg …
[HTML][HTML] Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
R Fleischmann, PJ Mease, S Schwartzman… - Clinical …, 2017 - Springer
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This
post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of …
post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of …
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty‐four–month, phase …
D van der Heijde, V Strand, Y Tanaka… - Arthritis & …, 2019 - Wiley Online Library
Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA).
The phase III, 24‐month, placebo‐controlled Oral Rheumatoid Arthritis (ORAL) Scan trial …
The phase III, 24‐month, placebo‐controlled Oral Rheumatoid Arthritis (ORAL) Scan trial …
[PDF][PDF] Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised …
GV Wallenstein, KS Kanik, B Wilkinson… - Clin Exp …, 2016 - clinexprheumatol.org
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with
active rheumatoid arthritis Page 1 Clinical and Experimental Rheumatology 2016; 34: 430-442 …
active rheumatoid arthritis Page 1 Clinical and Experimental Rheumatology 2016; 34: 430-442 …
相关搜索
- rheumatoid arthritis methotrexate in patients
- rheumatoid arthritis tofacitinib in combination
- rheumatoid arthritis antirheumatic drugs
- safety outcomes methotrexate in patients
- rheumatoid arthritis safety outcomes
- safety outcomes tofacitinib in combination
- tofacitinib efficacy methotrexate or glucocorticoids
- clinical efficacy methotrexate in patients
- rheumatoid arthritis inadequate response
- efficacy and safety tofacitinib in patients
- rheumatoid arthritis effect of discontinuation
- rheumatoid arthritis clinical efficacy
- antirheumatic drugs tofacitinib in combination
- clinical efficacy tofacitinib in combination
- rheumatoid arthritis combination with methotrexate
- rheumatoid arthritis tofacitinib in patients